Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease

Molecular Diagnosis and Therapy

Volumn 10, Issue 5, 2006, Pages 281-292

  Kolarcik, Christi ^a   Bowser, Robert ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; CYSTATIN C; CYTOKINE; CYTOSKELETON PROTEIN; DEOXYGUANOSINE DERIVATIVE; MALONALDEHYDE; PLASMA PROTEIN; PREALBUMIN; PROTEOME; RILUZOLE; TRANSFORMING GROWTH FACTOR BETA;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DISEASE MARKER; DRUG MECHANISM; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOME; HUMAN; MASS SPECTROMETRY; MORTALITY; MOTOR NEURON DISEASE; MOTOR PERFORMANCE; NERVE CELL DEGENERATION; NEUROLOGIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PLASMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SURVIVAL;

EID: 33749860079     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256203     Document Type: Review

References (110)

1. Sorensen EJ, Stalker AP, Kurland LT, et al. Amyotrophic lateral sclerosis in Olmstead County, Minnesota, 1925 to 1998. Neurology 2002; 59 (2): 280-2
2. Annegers JF, Appel SH, Lee JR, et al. Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985-1988. Arch Neurol 1991; 48 (6): 589-93
3. Traynor BJ, Codd MB, Corr B, et al. Incidence and prevalence of ALS in Ireland, 1995-1997: a population-based study. Neurology 1999; 52 (3): 504-9
4. Simpson EP, Yen AA, Appel SH. Oxidative stress: a common denominator in the pathogenesis of amyotrophic lateral sclerosis. Curr Opin Rheumatol 2003; 15: 730-6
5. Cudkowicz M, Qureshi M, Shefner J. Measures and markers in amyotrophic lateral sclerosis. NeuroRx 2004; 1 (2): 273-83
6. Magnus T, Beck M, Giess R, et al. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 2002; 25 (5): 709-14
7. Strong MJ, Kesavapany S, Pant HC. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J Neuropathol Exp Neurol 2005; 64 (8): 649-64
8. Olney JW. Excitatory amino acids and neuropsychiatric disorders. Biol Psychiatry 1989; 26 (5): 505-25
9. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 1999; 81 (3): 163-221
10. Blackstock WP, Weir MP. Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol 1999; 17 (3): 121-7
11. Lim MS, Elenitoba-Johnson K. Proteomics in pathology research. Lab Invest 2004; 84: 1227-44
12. Atkinson AJJ, Warren G, Colburn WA, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95
13. Mandrioli J, Faglioni P, Merelli E, et al. The epidemiology of ALS in Modena, Italy. Neurology 2003; 60 (4): 683-9
14. Mitsumoto H. Diagnosis and progression of ALS. Neurology 1997; 48 Suppl. 4: S2-8
15. Rowland L. Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1998; 160 Suppl. 1: 6-24
16. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994; 124: 96-107
17. Bowser R, Cudkowicz M, Kaddurah-Daouk R. Biomarkers for amyotrophic lateral sclerosis. Expert Rev Mol Diagn 2006; 6 (3): 387-98
18. Bensimon G, Lacomblez L, Meininger V, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585-91
19. Ludolph AC, Riepe MW. Do the benefits of currently available treatments justify early diagnosis and treatment of amyotrophic lateral sclerosis? Arguments against. Neurology 1999; 53 Suppl. 5: S46-9
20. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2001; 4: CD001447
21. Traynor BJ, Alexander M, Corr B, et al. An outcome study of riluzole in amyotrophic lateral sclerosis: a population-based study in Ireland, 1996-2000. J Neurol 2003; 250: 473-9
22. Zoing MC, Burke D, Pamphlett R, et al. Riluzole therapy for motor neuron disease: an early Australian experience (1996-2002). J Clin Neurosci 2006; 13 (1): 78-83
23. Simmons Z. Management strategies for patients with amyotrophic lateral sclerosis from diagnosis through death. Neurologist 2005; 11 (5): 257-70
24. Bensimon G, Lacomblez L, Delumeau JC, et al. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol 2002; 249 (5): 609-15
25. Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler 2003; 4 (3): 191-206
26. Roberts R, Cain K, Coyle B, et al. Early drug safety evaluation: biomarkers, signatures and fingerprints. Drug Metab Rev 2003; 35: 269-75
27. Kroeger M, Gluckmann M. Identification and prevalidation of safety biomarkers. Eur Pharmaceutical Rev 2006; 2: 22-9
28. Wetmore BA, Merrick BA. Toxicoproteomics: proteomics applied to toxicology and pathology. Toxicol Pathol 2004; 32: 619-42
29. Baker M. In biomarkers we trust? Nat Biotechnol 2005; 23: 297-304
30. Miller RG, Moore DH, Gelinas DF, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001; 56 (7): 843-8
31. Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology 2004; 63 (9): 1656-61
32. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006; 60 (1): 22-31
33. Paul B, Dhir R, Landsittel D, et al. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res 2005; 65 (10): 4097-100
34. Shiomi K, Miyamoto H, Segawa T, et al. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci 2006; 97 (9): 928-32
35. Lau SK, Woo PC, Wong BH, et al. Detection of severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in SARS patients by enzyme-linked immunosorbent assay. J Clin Microbiol 2004; 42 (7): 2884-9
36. Studentsov YY, Schiffman M, Strickler HD, et al. Enhanced enzyme-linked immunosorbent assay for detection of antibodies to virus-like particles of human papillomavirus. J Clin Microbiol 2002; 40 (5): 1755-60
37. Sanchez JC. Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2004; 4 (8): 2229-33
38. Dekker LJ, Boogerd W, Stockhammer G, et al. MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol Cell Proteomics 2005; 4: 1341-9
39. Anderson NL, Anderson NG. The human plasma proteome. Mol Cell Proteomics 2002; 1: 845-67
40. Shen Y, Kim J, Strittmatter EF, et al. Characterization of the human blood plasma proteome. Proteomics 2005; 5: 4034-45
41. Kozak KR, Su F, Whitelegge JP, et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005; 5: 4589-96
42. Allard L, Burkhard PR, Lescuyer P, et al. PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin Chem 2005; 51 (11): 2043-51
43. Lopez MF, Mikulskis A, Kuzdzal S, et al. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem 2005; 51 (10): 1946-54
44. Apostolski S, Nikolic J, Bugarski-Prokopljevic C, et al. Serum and CSF immunological findings in ALS. Acta Neurol Scand 1991; 83 (2): 96-8
45. 2+ enhancement. Acta Neuropathol 2004; 107 (1): 35-46
46. Goldknopf IL, Sheta EA, Bryson J, et al. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Biochem Biophys Res Commun 2006; 342: 1034-9
47. Houi K, Kobayashi T, Kato S, et al. Increased plasma TGF-beta1 in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2002; 106 (5): 299-301
48. Ilzecka J, Stelmasiak Z, Dobosz B. Transforming growth factor-beta1 (TGF-beta1) in patients with amyotrophic lateral sclerosis. Cytokine 2003; 20 (5): 239-43
49. Lacomblez L, Doppler V, Beucler I, et al. APOE: a potential marker of disease progression in ALS. Neurology 2002; 58 (7): 1112-4
50. Ono S, Imai T, Shimizu N, et al. Decreased plasma levels of fibronectin in amyotrophic lateral sclerosis. Acta Neurol Scand 2000; 101 (6): 391-4
51. Simpson EP, Henry YK, Henkel JS, et al. Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 2004; 62 (10): 1758-65
52. Sohmiya M, Tanaka M, Suzuki Y, et al. An increase of oxidized coenzyme-Q occurs in the plasma of sporadic ALS patients. J Neurol Sci 2005; 228 (1): 49-53
53. Camu W, Billiard M, Baldy-Moulinier M. Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis. Acta Neurol Scand 1993; 88: 18-25
54. Palma A, de Carvalho M, Barata N, et al. Biochemical characterization of plasma in amyotrophic lateral sclerosis: amino acid and protein composition. Amyotroph Lateral Scler 2005; 6: 104-10
55. Rozen S, Cudkowicz ME, Bogdanov M, et al. Metabolomic analysis and signatures in motor neuron disease. Metabolomics 2005; 1 (2): 101-8
56. Chao CC, Hu S, Frey WHN, et al. Transforming growth factor beta in Alzheimer's disease. Clin Diagn Lab Immunol 1994; 1 (1): 109-10
57. Flanders KC, Lippa CF, Smith TW, et al. Altered expression of transforming growth factor-beta in Alzheimer's disease. Neurology 1995; 45: 1561-9
58. Bottner M, Krieglstein K, Unsicker K. The transforming growth factor-βs: structure, signaling, and roles in nervous system development and functions. J Neurochem 2000; 75: 2227-40
59. Deniselle MC, Lavista-Llanos S, Ferrini MG, et al. In vitro differences between astrocytes of control and wobbler mice spinal cord. Neurochem Res 1999; 24: 1535-41
60. Heath PR, Shaw PJ. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 2002; 26 (4): 438-58
61. Plaitakis A, Constantakakis E, Smith J. The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann Neurol 1988; 24: 446-9
62. Perry TL, Krieger C, Hansen S, et al. Amyotrophic lateral sclerosis: amino acid levels in plasma and cerebrospinal fluid. Ann Neurol 1990; 28: 12-7
63. Ilzecka J, Stelmasiak Z, Solski J, et al. Plasma amino acid percentages in amyotrophic lateral sclerosis patients. Neurol Sci 2003; 24: 293-5
64. Shaw PJ, Forrest V, Ince PG, et al. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995; 4: 209-16
65. Davson H, Segal MB. Physiology of the CSF and blood-brain barriers. Boca Raton (FL): CRC Press; 1995
66. Yuan X, Russell T, Wood G, et al. Analysis of the human lumbar cerebrospinal fluid proteome. Electrophoresis 2002; 23: 1185-96
67. Hu Y, Malone JP, Fagan AM, et al. Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. Mol Cell Proteomics 2005; 4: 2000-9
68. Oteiza PI, Uchitel OD, Carrasquedo F, et al. Evaluation of antioxidants, protein, and lipid oxidation products in blood from sporadic amiotrophic lateral sclerosis patients. Neurochem Res 1997; 22 (4): 535-9
69. Bogdanov M, Brown RH, Matson WR, et al. Increased oxidative damage to DNA in ALS patients. Free Radical Biol Med 2000; 29 (7): 652-8
70. Sussmuth SD, Tumani H, Ecker D, et al. Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci Lett 2003; 353: 57-60
71. Jimenez-Jimenez FJ, Hernanz A, Medina-Acebron S, et al. Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2005; 111: 114-7
72. Kapaki E, Paraskevas GP, Michalopoulou M, et al. Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur Neurol 2000; 43: 228-32
73. Sjogren M, Davidsson P, Wallin A, et al. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement Geriatr Cogn Disord 2002; 13: 112-8
74. Brettschneider J, Petzold A, Submuth SD, et al. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006; 66: 852-6
75. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003; 987: 25-31
76. Rosengren LE, Karlsson JE, Karlsson JO, et al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996; 67: 2013-8
77. Kuncl RW, Bilak MM, Bilak SR, et al. Pigment epithelium-derived factor is elevated in CSF of patients with amyotrophic lateral sclerosis. J Neurochem 2002; 81: 178-84
78. Brockington A, Wharton SB, Fernando M, et al. Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2006; 65 (1): 26-36
79. Sekizawa T, Openshaw H, Ohbo K, et al. Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurological Sci 1998; 154 (2): 194-9
80. Tsuboi Y, Yamada T. Increased concentration of C4d complement protein in CSF in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1994; 57: 859-61
81. Baron P, Bussini S, Cardin V, et al. Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. Muscle Nerve 2005; 32 (4): 541-4
82. Ramstrom M, Ivonin I, Johansson A, et al. Cerebrospinal fluid protein patterns in neurodegenerative disease revealed by liquid chromatography-Fourier transform ion cyclotron resonance mass spectrometry. Proteomics 2005; 4: 4010-8
83. Ranganathan S, Williams E, Ganchev P, et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 2005; 95: 1461-71
84. Pasinetti GM, Ungar LH, Lange DJ, et al. Identification of potential CSF biomarkers in ALS. Neurology 2006; 66: 1218-22
85. Bowling AC, Schulz JB, Brown RHJ, et al. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1993; 61: 2322-5
86. Shibata N, Nagai R, Uchida K, et al. Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 2001; 917: 97-104
87. Ferrante RJ, Browne SE, Shinobu LA, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997; 69: 2064-74
88. Wood-Allum CA, Barber SC, Kirby J, et al. Impairment of mitochondrial antioxidant defence in SOD1-related motor neuron injury and amelioration by ebselen. Brain 2006; 129: 1693-709
89. Bilak MM, Corse AM, Bilak SR, et al. Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamate-mediated neurodegeneration. J Neuropathol Exp Neurol 1999; 58: 719-28
90. Houenou LJ, D'Costa AP, Li L, et al. Pigment epithelium-derived factor promotes the survival and differentiation of developing spinal motor neurons. J Comp Neurol 1999; 412: 506-14
91. Hensley K, Floyd RA, Gordon B, et al. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Neurochem 2002; 82 (2): 365-74
92. Rogers MA, Clarke P, Noble J, et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res. 2003; 63: 6971-83
93. Puchades M, Hansson SF, Nilsson CL, et al. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Mol Brain Res 2003; 118: 140-6
94. Carrette O, Demalte I, Scherl A, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003; 3 (8): 1486-94
95. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004; 1 (2): 213-25
96. Provost F, Buchanan B. Inductive policy: the pragmatics of bias selection. J Mach Learn Res 1995; 20: 35-61
97. Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci 2004; 41: 467-550
98. Carrette O, Burkhard PR, Hughes S, et al. Truncated cystatin C in cerebrospinal fluid: technical artefact or biological process? Proteomics 2005; 5: 3060-5
99. Levy E. Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients. J Neuropathol Exp Neurol 2001; 60: 94-104
100. van Welsem ME. The relationship between Bunina bodies, skein-like inclusions and neuronal loss in amyotrophic lateral sclerosis. Acta Neuropathol 2002; 103 (6): 583-9
101. Bergen HR, Zeldenrust SR, Butz ML, et al. Identification of transthyretin variants by sequential proteomic and genomic analysis. Clin Chem 2004; 50 (9): 1544-52
102. Lim A, Prokaeva T, McCombs ME, et al. Characterization of transthyretin variants in familial transthyretin amyloidosis by mass spectrometric peptide mapping and DNA sequence analysis. Anal Chem 2002; 74: 741-51
103. Tachibana N, Tokuda T, Yoshida K, et al. Usefulness of MALDI/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy. Amyloid 1999; 6: 282-8
104. Saraiva MJ. Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum Mutat 2001; 17: 493-503
105. Stein TD, Johnson JA. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci 2002; 22: 7380-8
106. Marcinkiewicz M, Touraine P, Chretien M. Pan-neuronal mRNA expression of the secretory polypeptide 7B2. Neurosci Lett 1994; 177 (1-2): 91-4
107. Hwang JR, Lindberg I. Inactivation of the 7B2 inhibitory CT peptide depends on a functional furin cleavage site. J Neurochem 2001; 79 (2): 437-44
108. Gonatas NK. Fragmentation of the Golgi apparatus of motor neurons in amyotrophic lateral sclerosis. Am J Pathol 1992; 140 (3): 731-7
109. Yuan X, Desiderio DM. Human cerebrospinal fluid peptidomics. J Mass Spectrom 2005; 40: 176-81
110. Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J Nat Cancer Inst 2005; 97 (4): 315-9